» Articles » PMID: 32986793

Clinical Epidemiology of Hospitalized Patients With Coronavirus Disease 2019 (COVID-19) in Japan: Report of the COVID-19 Registry Japan

Abstract

Background: There is limited understanding of the characteristics of patients with coronavirus disease 2019 (COVID-19) requiring hospitalization in Japan.

Methods: This study included 2638 cases enrolled from 227 healthcare facilities that participated in the COVID-19 Registry Japan (COVIREGI-JP). The inclusion criteria for enrollment of a case in COVIREGI-JP are both (1) a positive severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) test and (2) inpatient treatment at a healthcare facility.

Results: The median age of hospitalized patients with COVID-19 was 56 years (interquartile range [IQR], 40-71 years). More than half of cases were male (58.9%, 1542/2619). Nearly 60% of the cases had close contact to confirmed or suspected cases of COVID-19. The median duration of symptoms before admission was 7 days (IQR, 4-10 days). The most common comorbidities were hypertension (15%, 396/2638) and diabetes without complications (14.2%, 374/2638). The number of nonsevere cases (68.2%, n = 1798) was twice the number of severe cases (31.8%, n = 840) at admission. The respiratory support during hospitalization includes those who received no oxygen support (61.6%, 1623/2636) followed by those who received supplemental oxygen (29.9%, 788/2636) and invasive mechanical ventilation/extracorporeal membrane oxygenation (8.5%, 225/2636). Overall, 66.9% (1762/2634) of patients were discharged home, while 7.5% (197/2634) died.

Conclusions: We identified the clinical epidemiological features of COVID-19 in hospitalized patients in Japan. When compared with existing inpatient studies in other countries, these results demonstrated fewer comorbidities and a trend towards lower mortality.

Citing Articles

Cost-effectiveness Analysis of Nirmatrelvir/Ritonavir Compared with Molnupiravir in Patients at High Risk for Progression to Severe COVID-19 in Japan.

Yuasa A, Matsuda H, Fujii Y, Mugwagwa T, Kado Y, Yoshida M J Health Econ Outcomes Res. 2025; 12(1):75-85.

PMID: 40012632 PMC: 11864595. DOI: 10.36469/001c.129067.


Silicone Breast Implant Rupture Triggered by Infection Leading to Skin Ulceration: A Case Report.

Nagata Y, Sezaki S, Kinoshita I, Saeki T, Fujikawa T Cureus. 2025; 16(12):e75556.

PMID: 39803107 PMC: 11723711. DOI: 10.7759/cureus.75556.


Association Between Dietary Habit Changes and COVID-19 Prophylaxis During the Pandemic Among Japanese Maintenance Hemodialysis Patients.

Inoue T, Ando T, Murakami T, Hirakawa S, Fujita Y, Shin T Cureus. 2025; 16(12):e75489.

PMID: 39791086 PMC: 11717368. DOI: 10.7759/cureus.75489.


Gender differences and mental distress during COVID-19: a cross-sectional study in Japan.

Kanata T, Takeda K, Fujii T, Iwata R, Hiyoshi F, Iijima Y BMC Psychiatry. 2024; 24(1):776.

PMID: 39506718 PMC: 11539831. DOI: 10.1186/s12888-024-06200-5.


Association Between COVID-19 and Diabetes Management Indices in Japanese Type 2 Diabetes Mellitus Patients: A Single-Center, Retrospective Study.

Furumachi K, Kagatsume T, Higuchi A, Kozaru M, Kumagai E, Hosohata K Infect Drug Resist. 2024; 17:3759-3767.

PMID: 39224903 PMC: 11368151. DOI: 10.2147/IDR.S475917.


References
1.
Harris P, Taylor R, Thielke R, Payne J, Gonzalez N, Conde J . Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2008; 42(2):377-81. PMC: 2700030. DOI: 10.1016/j.jbi.2008.08.010. View

2.
Wiersinga W, Rhodes A, Cheng A, Peacock S, Prescott H . Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A Review. JAMA. 2020; 324(8):782-793. DOI: 10.1001/jama.2020.12839. View

3.
Garg S, Kim L, Whitaker M, OHalloran A, Cummings C, Holstein R . Hospitalization Rates and Characteristics of Patients Hospitalized with Laboratory-Confirmed Coronavirus Disease 2019 - COVID-NET, 14 States, March 1-30, 2020. MMWR Morb Mortal Wkly Rep. 2020; 69(15):458-464. PMC: 7755063. DOI: 10.15585/mmwr.mm6915e3. View

4.
Beigel J, Tomashek K, Dodd L . Remdesivir for the Treatment of Covid-19 - Preliminary Report. Reply. N Engl J Med. 2020; 383(10):994. DOI: 10.1056/NEJMc2022236. View

5.
Charlson M, Pompei P, Ales K, MacKenzie C . A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987; 40(5):373-83. DOI: 10.1016/0021-9681(87)90171-8. View